ADAM17 and neoplasm: While intratumoral administration of low-dose sumIL-2 alone could effectively control the tumor growth, the combination of sumIL-2 treatment with ADAM17 ablation in T cells further enhanced the antitumor efficacy (Fig. 5n and supplementary Fig. 8d).